Cleaved-CASP2 (G170) Antibody

What is Cleaved-CASP2 (G170) Antibody and what specifically does it detect?

The Cleaved-CASP2 (G170) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of activated Caspase-2 p18 protein fragments resulting from cleavage adjacent to glycine at position 170 (G170). This antibody was generated using a synthesized peptide derived from the human Caspase-2 p18 N-terminal region, specifically targeting the amino acid range of 151-200 . The antibody demonstrates high specificity for the cleaved form of Caspase-2, particularly recognizing the neo-epitope created after proteolytic processing. Caspase-2 functions as a regulator in the cascade of caspases responsible for apoptosis execution, potentially by either activating proteins required for cell death or inactivating proteins necessary for cell survival . The cleaved form of Caspase-2 represents the activated state of this protease, making this antibody particularly valuable for studying apoptotic signaling pathways where Caspase-2 plays a crucial initiator role. Understanding the specific epitope recognition properties of this antibody is essential for correct interpretation of experimental results when investigating caspase-mediated cell death mechanisms.

What applications is the Cleaved-CASP2 (G170) Antibody validated for in research settings?

The Cleaved-CASP2 (G170) Antibody has been specifically validated for Western Blot (WB) and Enzyme-Linked Immunosorbent Assay (ELISA) research applications . In Western Blot applications, this antibody enables researchers to detect and quantify the levels of cleaved Caspase-2 in cell or tissue lysates, providing critical information about the activation status of this initiator caspase during apoptotic processes. The antibody's affinity purification using epitope-specific immunogen ensures high specificity for the cleaved form of Caspase-2, minimizing background signal from uncleaved protein . For ELISA applications, the antibody provides a sensitive method for quantitative analysis of cleaved Caspase-2 levels in complex biological samples. When developing experimental protocols, researchers should note that this antibody is strictly intended for scientific research purposes only (RUO) and must not be used in diagnostic or therapeutic applications . While not explicitly validated in the provided literature, similar caspase-specific antibodies have been successfully used in immunoprecipitation experiments to isolate cleaved caspase substrates from apoptotic cell lysates, suggesting potential additional applications for this antibody in specialized research contexts .

What is the recommended working dilution for the Cleaved-CASP2 (G170) Antibody in different experimental techniques?

For optimal experimental results, researchers should adhere to the recommended dilution ranges for the Cleaved-CASP2 (G170) Antibody, which have been established to maximize signal-to-noise ratio while minimizing background interference. In Western Blot applications, the antibody should be used at a dilution range of 1:500 to 1:2000, allowing researchers to adjust the concentration based on the abundance of cleaved Caspase-2 in their specific samples . These dilution parameters have been optimized to ensure sufficient sensitivity for detecting even low levels of activated Caspase-2 following apoptotic stimuli. For ELISA applications, a substantially higher dilution of 1:40000 is recommended, reflecting the enhanced sensitivity of this detection method and the need to prevent signal saturation that could compromise quantitative analysis . The antibody is supplied at a concentration of 1 mg/mL, which should be considered when calculating working dilutions for specific experiments . When establishing a new experimental system, researchers are advised to perform preliminary titration experiments to determine the optimal antibody concentration for their particular cell type, tissue, or treatment conditions, as the abundance of cleaved Caspase-2 may vary significantly depending on the strength and duration of apoptotic stimuli.

How should the Cleaved-CASP2 (G170) Antibody be stored to maintain its activity?

Proper storage of the Cleaved-CASP2 (G170) Antibody is crucial for maintaining its specificity and sensitivity over time. The manufacturer recommends storing the antibody at -20°C for up to one year from the date of receipt . This low temperature is essential for preserving the structural integrity of the antibody and preventing degradation that could compromise its binding affinity for the cleaved Caspase-2 epitope. The antibody is supplied in a stabilizing formulation consisting of PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain protein stability during freeze-thaw cycles . Despite these protective measures, researchers should take care to avoid repeated freeze-thaw cycles, which can cause protein denaturation and progressive loss of antibody activity. Best practices include aliquoting the antibody into smaller volumes upon receipt to minimize the number of freeze-thaw cycles any portion undergoes. When handling the antibody, it's important to note that the formulation contains sodium azide, which is a toxic substance, and appropriate safety precautions should be observed. For day-to-day use during an experimental period, storing working dilutions at 4°C for up to one week is generally acceptable, though sensitivity may gradually decline compared to freshly prepared dilutions.

How can researchers validate the specificity of Cleaved-CASP2 (G170) Antibody in their experimental systems?

Validating antibody specificity is a critical step when studying cleaved Caspase-2 to ensure that experimental observations genuinely reflect Caspase-2 activation rather than cross-reactivity or non-specific binding. The first validation approach involves using apoptosis induction coupled with caspase inhibition as an experimental control. Researchers can treat cells with apoptosis-inducing agents that activate Caspase-2, such as 5-FU/TRAIL combination, and compare antibody reactivity in the presence or absence of a pan-caspase inhibitor like QVD-OPH . Specific binding should be detectable only in apoptotic samples without caspase inhibition. A second validation approach employs recombinant protein systems, where researchers can incubate recombinant Caspase-2 to generate cleaved fragments and confirm antibody recognition of these processed forms . Additionally, siRNA or CRISPR-based Caspase-2 knockdown/knockout models provide a powerful negative control, as any signal detected in these systems would indicate non-specific binding. Western blot analysis should reveal the expected molecular weight band (~18 kDa) corresponding to the cleaved p18 fragment of Caspase-2, with minimal or no reactivity with the full-length procaspase form . For researchers seeking the highest level of validation, comparing reactivity patterns with multiple antibodies targeting different epitopes of Caspase-2 can provide convergent evidence of specificity and increase confidence in experimental findings related to Caspase-2 activation and function.

How can temporal dynamics of Caspase-2 activation be measured using the Cleaved-CASP2 (G170) Antibody?

Monitoring the temporal dynamics of Caspase-2 activation provides critical insights into its role as an initiator caspase in various apoptotic pathways. To establish a detailed activation timeline, researchers can perform kinetic experiments using Western blot analysis with the Cleaved-CASP2 (G170) Antibody at multiple time points following apoptotic stimulation . This approach can reveal how quickly Caspase-2 undergoes cleavage relative to other caspases like caspase-8 and caspase-9, helping to establish the sequence of caspase activation events. Previous studies have demonstrated that Caspase-2 cleavage can be detected as early as 5 hours after treatment with certain apoptotic stimuli like α-toxin . Complementary to protein detection methods, researchers can incorporate fluorogenic substrate assays using VDVAD-fmk (a putative Caspase-2 substrate) to measure enzymatic activity, though it's important to note that this substrate is not entirely specific to Caspase-2 . For more sophisticated temporal analysis, live-cell imaging combined with fluorescent reporters of caspase activity can be employed alongside post-experiment validation using the Cleaved-CASP2 (G170) Antibody. When designing kinetic experiments, researchers should include both early time points (1-6 hours) to capture initial activation events and later time points (up to 24 hours) to observe sustained activation patterns or secondary cleavage events. This comprehensive temporal profiling enables researchers to position Caspase-2 accurately within the hierarchical cascade of apoptotic signaling and determine whether it functions as an initiator or amplifier in specific cellular contexts.

What techniques can be used to investigate Caspase-2 dimerization using the Cleaved-CASP2 (G170) Antibody?

Investigating Caspase-2 dimerization is crucial for understanding its activation mechanism, as dimerization precedes and is required for auto-catalytic cleavage and full enzymatic activity . While the Cleaved-CASP2 (G170) Antibody primarily detects the cleaved form resulting from dimerization-induced processing, researchers can employ several techniques to study the dimerization process itself. One approach involves using chemical crosslinking agents to stabilize transient protein-protein interactions, followed by Western blot analysis with the Cleaved-CASP2 (G170) Antibody to detect both monomeric cleaved Caspase-2 (~18 kDa) and potential dimeric forms at higher molecular weights. Co-immunoprecipitation experiments can be designed to pull down Caspase-2 complexes using antibodies against known dimerization platforms like PIDD1 or RAIDD, followed by detection of cleaved Caspase-2 using the G170 antibody to establish the relationship between dimerization platform recruitment and subsequent cleavage . For more sophisticated analysis, researchers can employ size exclusion chromatography to separate protein complexes based on molecular weight, followed by Western blotting of fractions to detect cleaved Caspase-2 within high molecular weight complexes versus monomeric forms. This technique has successfully demonstrated that endogenous Caspase-2 can be recruited to high-molecular-weight complexes during apoptosis induced by pore-forming toxins, independent of the canonical PIDDosome . Bimolecular fluorescence complementation (BiFC) or Förster resonance energy transfer (FRET) approaches can provide complementary data on Caspase-2 dimerization in living cells, which can then be correlated with cleavage detection using the G170 antibody in fixed samples or cell lysates from parallel experiments.

How does Caspase-2 activation differ from other initiator caspases and how can Cleaved-CASP2 (G170) Antibody help distinguish these pathways?

Caspase-2 exhibits unique activation characteristics that distinguish it from other initiator caspases, and the Cleaved-CASP2 (G170) Antibody provides a valuable tool for exploring these differences. Unlike executioner caspases (caspase-3 and -7) that are activated by cleavage alone, Caspase-2 resembles initiator caspases-8 and -9 in requiring dimerization as the primary activation mechanism, with subsequent cleavage serving to stabilize the active dimer and enhance catalytic efficiency . The Cleaved-CASP2 (G170) Antibody specifically recognizes the cleaved form resulting from this activation process, enabling researchers to track Caspase-2 activation independently from other caspases. A distinctive feature of Caspase-2 is its ability to undergo auto-processing without requiring activity from other caspases, although it can also be cleaved by caspase-3 in certain contexts . This dual processing mechanism can be investigated using the G170 antibody in combination with specific caspase inhibitors or genetic models lacking other caspases. For example, studies in MCF-7 cells lacking caspase-3 showed that Caspase-2 cleavage induced by PIDD1 overexpression was not impaired, demonstrating its capacity for auto-processing . Conversely, thymocytes deficient in APAF-1 or caspase-9 showed defective Caspase-2 processing in response to intrinsic apoptosis stimuli, revealing context-dependent processing mechanisms . By enabling specific detection of cleaved Caspase-2, the G170 antibody allows researchers to dissect these complex relationships between different caspase activation pathways and determine whether Caspase-2 is functioning as a primary initiator or as part of an amplification loop in various apoptotic contexts.

What is the significance of studying Caspase-2's role in tumor suppression using the Cleaved-CASP2 (G170) Antibody?

Investigating Caspase-2's tumor suppressive functions represents a significant area of research where the Cleaved-CASP2 (G170) Antibody can provide valuable insights into the underlying molecular mechanisms. Recent research has highlighted Caspase-2's role in cleaving MDM2, a negative regulator of the tumor suppressor p53, resulting in stabilization and activation of p53 following DNA damage . By specifically detecting the activated form of Caspase-2, the G170 antibody enables researchers to correlate Caspase-2 activation with subsequent MDM2 cleavage and p53 stabilization in response to genotoxic stressors. Studies have demonstrated that Caspase-2 mediates cleavage of MDM2 at an Asp367-Gly368 site, generating a p60 fragment that lacks the RING domain responsible for p53 degradation, thereby promoting sustained rather than oscillatory p53 protein dynamics . This sustained p53 response prevents continued cell cycling in the presence of DNA damage, providing a mechanism for Caspase-2's tumor suppressive function. The Cleaved-CASP2 (G170) Antibody can be used in time-course experiments to establish the temporal relationship between Caspase-2 activation, MDM2 cleavage, and p53 stabilization, helping to delineate the precise sequence of events in this tumor suppressive pathway. Additionally, immunohistochemical analysis of tumor samples using this antibody could reveal correlations between Caspase-2 activation status and tumor aggressiveness or treatment response. By facilitating the investigation of Caspase-2's interactions with key tumor suppressors and oncogenes, the G170 antibody contributes to our understanding of how dysregulation of apoptotic pathways promotes tumorigenesis and how these pathways might be targeted therapeutically.

What are common technical challenges when using the Cleaved-CASP2 (G170) Antibody in Western blot applications?

When employing the Cleaved-CASP2 (G170) Antibody in Western blot applications, researchers may encounter several technical challenges that can affect detection specificity and sensitivity. One common issue involves the relatively low abundance of cleaved Caspase-2 in many experimental systems, particularly at early time points following apoptotic stimulation. This challenge can be addressed by optimizing protein loading (typically 50-100 μg of total protein), using enhanced chemiluminescence detection systems, and ensuring complete transfer of proteins to membranes during the blotting process. The antibody's recommended dilution range of 1:500-1:2000 for Western blot should be carefully titrated for each experimental system to achieve optimal signal-to-noise ratio . Another significant challenge involves distinguishing specific cleavage products from non-specific bands or cross-reactivity with other caspases, given the structural similarities within the caspase family. To address this issue, researchers should include both positive controls (lysates from cells treated with known Caspase-2 activators) and negative controls (lysates from cells co-treated with pan-caspase inhibitors like QVD-OPH) . When analyzing complex samples, inclusion of Caspase-2 knockout/knockdown controls is particularly valuable for confirming band specificity. Researchers should also be aware that the timing of sample collection is crucial, as Caspase-2 activation can be transient in some contexts, and delayed collection may miss the window of maximal cleavage. Finally, proper sample preparation is essential to prevent artificial caspase activation during cell lysis; samples should be collected in the presence of protease inhibitors and processed rapidly on ice to preserve the in vivo activation state of Caspase-2.

How can researchers distinguish between Caspase-2 auto-processing and cleavage by other caspases using the Cleaved-CASP2 (G170) Antibody?

Distinguishing between Caspase-2 auto-processing and cleavage by downstream caspases represents a significant challenge that requires careful experimental design when using the Cleaved-CASP2 (G170) Antibody. This distinction is crucial for determining whether Caspase-2 is functioning as an initiator or is being cleaved as part of an amplification loop. A strategic approach involves temporal analysis of caspase activation using Western blotting with antibodies against multiple caspases (Caspase-2, -3, -8, and -9) in parallel . If Cleaved-CASP2 (G170) Antibody detects Caspase-2 cleavage before other caspases become activated, this suggests auto-processing rather than downstream cleavage. Selective caspase inhibition provides another powerful approach; researchers can use specific chemical inhibitors or dominant-negative constructs targeting individual caspases to determine which proteases are essential for Caspase-2 cleavage in their system. For instance, if Caspase-2 cleavage persists when Caspase-3 is inhibited, this supports an auto-processing mechanism. Genetic models lacking specific caspases offer the most definitive approach - studies in caspase-3-deficient MCF-7 cells have demonstrated that Caspase-2 cleavage induced by PIDD1 overexpression occurs independently of Caspase-3, confirming auto-processing capability . Conversely, studies in APAF-1 or Caspase-9 deficient thymocytes showed impaired Caspase-2 processing in response to intrinsic apoptosis stimuli, indicating context-dependent processing mechanisms . Site-directed mutagenesis of the Caspase-2 auto-processing site, combined with transfection experiments and detection using the G170 antibody, can further clarify the relative contribution of auto-processing versus cleavage by other caspases. Through these complementary approaches, researchers can establish whether Caspase-2 is functioning as a primary initiator or as part of a caspase amplification loop in their experimental system.

What considerations are important when using the Cleaved-CASP2 (G170) Antibody to detect caspase-2 activation in cell culture supernatants?

Detecting cleaved Caspase-2 in cell culture supernatants presents unique methodological challenges compared to cell lysate analysis, requiring specific considerations to ensure reliable results with the Cleaved-CASP2 (G170) Antibody. Release of cleaved Caspase-2 into the culture medium typically occurs during later stages of apoptosis when membrane integrity becomes compromised, making this approach particularly valuable for assessing cumulative apoptotic events rather than early activation dynamics. Studies with similar neo-epitope antibodies have demonstrated successful immunoprecipitation of caspase-cleaved products from apoptotic cell culture supernatants, suggesting this approach is feasible for Caspase-2 detection . A critical consideration involves sample concentration; cell culture supernatants typically contain lower concentrations of cellular proteins compared to lysates, potentially necessitating concentration steps prior to analysis. Techniques such as TCA precipitation, ultrafiltration, or immunoprecipitation can be employed to enrich cleaved Caspase-2 from culture media . Another important consideration involves potential degradation of cleaved Caspase-2 by extracellular proteases in the culture medium. Adding protease inhibitors to the medium prior to collection can help preserve cleaved forms for detection. Researchers should also be aware of potential interference from serum proteins when using media containing FBS; switching to serum-free conditions prior to inducing apoptosis can reduce this background, although the physiological impact of serum withdrawal should be considered. When analyzing culture supernatants, appropriate controls become particularly important - supernatants from non-apoptotic cells and from cells treated with pan-caspase inhibitors provide essential negative controls, while supernatants from cells treated with established Caspase-2 activators serve as positive controls. By addressing these methodological considerations, researchers can successfully employ the Cleaved-CASP2 (G170) Antibody to monitor Caspase-2 activation through detection of released cleavage products in culture supernatants.

What are the key advantages and limitations of using the Cleaved-CASP2 (G170) Antibody in apoptosis research?

The Cleaved-CASP2 (G170) Antibody offers several significant advantages for apoptosis research, particularly in its high specificity for the activated form of Caspase-2 resulting from cleavage adjacent to G170. This specificity enables researchers to directly monitor Caspase-2 activation status rather than merely detecting protein expression, providing crucial insights into apoptotic signaling dynamics . The antibody's validated applications in Western blot and ELISA provide complementary approaches for qualitative and quantitative analysis of Caspase-2 activation in complex biological samples . Additionally, the antibody's cross-reactivity with human, mouse, and rat Caspase-2 facilitates comparative studies across commonly used experimental models, enhancing translational relevance . Its utility in detecting the cleaved form specifically allows researchers to distinguish between the inactive zymogen and enzymatically active protease, a critical distinction for functional studies. Despite these advantages, researchers should be aware of certain limitations when employing this antibody. The primary limitation involves potential cross-reactivity with other caspase family members, necessitating careful validation with appropriate controls. Another limitation concerns the antibody's inability to distinguish between Caspase-2 cleaved through auto-processing versus cleavage by other caspases, requiring complementary approaches to establish the mechanism of Caspase-2 activation. Additionally, the antibody cannot directly capture the dimerization event that precedes and is required for Caspase-2 activation, limiting insights into the earliest stages of activation. Researchers should also consider that detection of cleaved Caspase-2 represents a downstream event in the apoptotic cascade and may not fully reflect the complexity of the upstream signaling events leading to caspase activation. By understanding both the capabilities and limitations of the Cleaved-CASP2 (G170) Antibody, researchers can design more effective experiments and interpret their results with appropriate context and caution.